APELLIS PHARMACEUTICALS INC (APLS) Fundamental Analysis & Valuation

NASDAQ:APLS • US03753U1060

Current stock price

40.96 USD
+0.01 (+0.02%)
At close:
40.96 USD
0 (0%)
After Hours:

This APLS fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

6

1. APLS Profitability Analysis

1.1 Basic Checks

  • In the past year APLS was profitable.
  • APLS had a positive operating cash flow in the past year.
  • In the past 5 years APLS reported 4 times negative net income.
  • APLS had negative operating cash flow in 4 of the past 5 years.
APLS Yearly Net Income VS EBIT VS OCF VS FCFAPLS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -200M -400M -600M

1.2 Ratios

  • APLS's Return On Assets of 2.08% is amongst the best of the industry. APLS outperforms 88.35% of its industry peers.
  • APLS's Return On Equity of 6.05% is amongst the best of the industry. APLS outperforms 91.26% of its industry peers.
  • APLS's Return On Invested Capital of 5.83% is amongst the best of the industry. APLS outperforms 91.26% of its industry peers.
Industry RankSector Rank
ROA 2.08%
ROE 6.05%
ROIC 5.83%
ROA(3y)-29.1%
ROA(5y)-51.55%
ROE(3y)-117.43%
ROE(5y)-222.36%
ROIC(3y)N/A
ROIC(5y)N/A
APLS Yearly ROA, ROE, ROICAPLS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -200 -400 -600 -800

1.3 Margins

  • APLS has a better Profit Margin (2.23%) than 88.54% of its industry peers.
  • APLS has a better Operating Margin (5.52%) than 89.13% of its industry peers.
  • APLS has a better Gross Margin (89.81%) than 91.46% of its industry peers.
  • APLS's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 5.52%
PM (TTM) 2.23%
GM 89.81%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1%
GM growth 5Y-0.05%
APLS Yearly Profit, Operating, Gross MarginsAPLS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -200 -400 -600 -800 -1K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. APLS Health Analysis

2.1 Basic Checks

  • APLS has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • The number of shares outstanding for APLS has been increased compared to 1 year ago.
  • The number of shares outstanding for APLS has been increased compared to 5 years ago.
  • The debt/assets ratio for APLS has been reduced compared to a year ago.
APLS Yearly Shares OutstandingAPLS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
APLS Yearly Total Debt VS Total AssetsAPLS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

2.2 Solvency

  • APLS has an Altman-Z score of 2.41. This is not the best score and indicates that APLS is in the grey zone with still only limited risk for bankruptcy at the moment.
  • The Altman-Z score of APLS (2.41) is better than 66.60% of its industry peers.
  • APLS has a debt to FCF ratio of 10.12. This is a negative value and a sign of low solvency as APLS would need 10.12 years to pay back of all of its debts.
  • Looking at the Debt to FCF ratio, with a value of 10.12, APLS belongs to the top of the industry, outperforming 90.29% of the companies in the same industry.
  • APLS has a Debt/Equity ratio of 0.98. This is a neutral value indicating APLS is somewhat dependend on debt financing.
  • The Debt to Equity ratio of APLS (0.98) is worse than 76.12% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.98
Debt/FCF 10.12
Altman-Z 2.41
ROIC/WACC0.6
WACC9.65%
APLS Yearly LT Debt VS Equity VS FCFAPLS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M 400M -400M

2.3 Liquidity

  • A Current Ratio of 3.14 indicates that APLS has no problem at all paying its short term obligations.
  • APLS's Current ratio of 3.14 is on the low side compared to the rest of the industry. APLS is outperformed by 61.55% of its industry peers.
  • A Quick Ratio of 2.70 indicates that APLS has no problem at all paying its short term obligations.
  • The Quick ratio of APLS (2.70) is worse than 65.24% of its industry peers.
Industry RankSector Rank
Current Ratio 3.14
Quick Ratio 2.7
APLS Yearly Current Assets VS Current LiabilitesAPLS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. APLS Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 108.97% over the past year.
  • The Revenue has grown by 28.46% in the past year. This is a very strong growth!
  • Measured over the past years, APLS shows a very strong growth in Revenue. The Revenue has been growing by 31.99% on average per year.
EPS 1Y (TTM)108.97%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-62.07%
Revenue 1Y (TTM)28.46%
Revenue growth 3Y137%
Revenue growth 5Y31.99%
Sales Q2Q%-5.94%

3.2 Future

  • Based on estimates for the next years, APLS will show a very strong growth in Earnings Per Share. The EPS will grow by 81.84% on average per year.
  • Based on estimates for the next years, APLS will show a quite strong growth in Revenue. The Revenue will grow by 8.75% on average per year.
EPS Next Y-1007.45%
EPS Next 2Y-99.48%
EPS Next 3Y85.44%
EPS Next 5Y81.84%
Revenue Next Year-14.07%
Revenue Next 2Y0.78%
Revenue Next 3Y5.59%
Revenue Next 5Y8.75%

3.3 Evolution

  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
APLS Yearly Revenue VS EstimatesAPLS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 500M 1B 1.5B
APLS Yearly EPS VS EstimatesAPLS Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 2 -2 4 -4 -6 -8

More info and screens

Find the best growth stocksShow best growing peers

5

4. APLS Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 315.08, the valuation of APLS can be described as expensive.
  • Based on the Price/Earnings ratio, APLS is valued cheaper than 88.16% of the companies in the same industry.
  • APLS's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 26.64.
  • APLS is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE 315.08
Fwd PE N/A
APLS Price Earnings VS Forward Price EarningsAPLS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 100 200 300

4.2 Price Multiples

  • 89.51% of the companies in the same industry are more expensive than APLS, based on the Enterprise Value to EBITDA ratio.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of APLS indicates a rather cheap valuation: APLS is cheaper than 89.71% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 116.33
EV/EBITDA 91.68
APLS Per share dataAPLS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

  • APLS has a very decent profitability rating, which may justify a higher PE ratio.
  • APLS's earnings are expected to grow with 85.44% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-99.48%
EPS Next 3Y85.44%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. APLS Dividend Analysis

5.1 Amount

  • No dividends for APLS!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

APLS Fundamentals: All Metrics, Ratios and Statistics

APELLIS PHARMACEUTICALS INC

NASDAQ:APLS (5/1/2026, 8:09:49 PM)

After market: 40.96 0 (0%)

40.96

+0.01 (+0.02%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Industry Strength55.9
Industry Growth13.04
Earnings (Last)04-30
Earnings (Next)07-29
Inst Owners98.98%
Inst Owner Change0.39%
Ins Owners3.97%
Ins Owner Change1.36%
Market Cap5.24B
Revenue(TTM)1.00B
Net Income(TTM)22.39M
Analysts71.11
Price Target39.38 (-3.86%)
Short Float %13.25%
Short Ratio2.62
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)8.55%
Min EPS beat(2)-21.01%
Max EPS beat(2)38.1%
EPS beat(4)2
Avg EPS beat(4)-13.31%
Min EPS beat(4)-101.36%
Max EPS beat(4)38.1%
EPS beat(8)5
Avg EPS beat(8)-6.29%
EPS beat(12)6
Avg EPS beat(12)-5.73%
EPS beat(16)7
Avg EPS beat(16)-5.68%
Revenue beat(2)1
Avg Revenue beat(2)4.35%
Min Revenue beat(2)-1.86%
Max Revenue beat(2)10.55%
Revenue beat(4)1
Avg Revenue beat(4)-3.72%
Min Revenue beat(4)-16.4%
Max Revenue beat(4)10.55%
Revenue beat(8)4
Avg Revenue beat(8)-0.96%
Revenue beat(12)7
Avg Revenue beat(12)8.54%
Revenue beat(16)9
Avg Revenue beat(16)6.28%
PT rev (1m)6.88%
PT rev (3m)3.2%
EPS NQ rev (1m)2.6%
EPS NQ rev (3m)26.2%
EPS NY rev (1m)0.64%
EPS NY rev (3m)-4.05%
Revenue NQ rev (1m)0.43%
Revenue NQ rev (3m)6.72%
Revenue NY rev (1m)0.4%
Revenue NY rev (3m)-0.16%
Valuation
Industry RankSector Rank
PE 315.08
Fwd PE N/A
P/S 5.22
P/FCF 116.33
P/OCF 115.52
P/B 14.15
P/tB 14.15
EV/EBITDA 91.68
EPS(TTM)0.13
EY0.32%
EPS(NY)-1.18
Fwd EYN/A
FCF(TTM)0.35
FCFY0.86%
OCF(TTM)0.35
OCFY0.87%
SpS7.85
BVpS2.9
TBVpS2.9
PEG (NY)N/A
PEG (5Y)N/A
Graham Number2.91016 (-92.9%)
Profitability
Industry RankSector Rank
ROA 2.08%
ROE 6.05%
ROCE 7.37%
ROIC 5.83%
ROICexc 15.34%
ROICexgc 15.34%
OM 5.52%
PM (TTM) 2.23%
GM 89.81%
FCFM 4.48%
ROA(3y)-29.1%
ROA(5y)-51.55%
ROE(3y)-117.43%
ROE(5y)-222.36%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1%
GM growth 5Y-0.05%
F-Score7
Asset Turnover0.93
Health
Industry RankSector Rank
Debt/Equity 0.98
Debt/FCF 10.12
Debt/EBITDA 6.35
Cap/Depr 20.09%
Cap/Sales 0.03%
Interest Coverage 1.34
Cash Conversion 79.54%
Profit Quality 201.06%
Current Ratio 3.14
Quick Ratio 2.7
Altman-Z 2.41
F-Score7
WACC9.65%
ROIC/WACC0.6
Cap/Depr(3y)28.62%
Cap/Depr(5y)52.72%
Cap/Sales(3y)0.09%
Cap/Sales(5y)0.79%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)108.97%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-62.07%
EPS Next Y-1007.45%
EPS Next 2Y-99.48%
EPS Next 3Y85.44%
EPS Next 5Y81.84%
Revenue 1Y (TTM)28.46%
Revenue growth 3Y137%
Revenue growth 5Y31.99%
Sales Q2Q%-5.94%
Revenue Next Year-14.07%
Revenue Next 2Y0.78%
Revenue Next 3Y5.59%
Revenue Next 5Y8.75%
EBIT growth 1Y133.6%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-235.52%
EBIT Next 3Y44.48%
EBIT Next 5Y28.94%
FCF growth 1Y151%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y151.59%
OCF growth 3YN/A
OCF growth 5YN/A

APELLIS PHARMACEUTICALS INC / APLS Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for APELLIS PHARMACEUTICALS INC?

ChartMill assigns a fundamental rating of 5 / 10 to APLS.


What is the valuation status of APELLIS PHARMACEUTICALS INC (APLS) stock?

ChartMill assigns a valuation rating of 5 / 10 to APELLIS PHARMACEUTICALS INC (APLS). This can be considered as Fairly Valued.


How profitable is APELLIS PHARMACEUTICALS INC (APLS) stock?

APELLIS PHARMACEUTICALS INC (APLS) has a profitability rating of 6 / 10.


What is the valuation of APELLIS PHARMACEUTICALS INC based on its PE and PB ratios?

The Price/Earnings (PE) ratio for APELLIS PHARMACEUTICALS INC (APLS) is 315.08 and the Price/Book (PB) ratio is 14.15.


Can you provide the financial health for APLS stock?

The financial health rating of APELLIS PHARMACEUTICALS INC (APLS) is 5 / 10.